Development of an algorithm for using PINP to monitor treatment of patients with teriparatide

Current Medical Research and Opinion

Volumn 22, Issue 1, 2006, Pages 61-66

  Eastell, Richard ^a   Krege, John H ^a,b   Chen, Peiqi ^b   Glass, Emmett V ^b   Reginster, Jean Yves ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Osteoporosis; Parathyroid hormone; PINP; Teriparatide

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE;

ALGORITHM; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MONITORING; FRAGILITY FRACTURE; HUMAN; META ANALYSIS; OSTEOBLAST; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; SIGNAL NOISE RATIO; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW;

EID: 30844433757     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X75096     Document Type: Conference Paper

References (21)

1. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
2. Lane NE, Sanchez S, Genant HK, et al. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 2000;11:434-42
3. Chen P, Satterwhite J, Licata AA, et al. Early changes in biochemical markers of bone formation predict bone mineral density response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005;20:962-70
4. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:1117-23
5. Delmas PD, Vrijens B, Roux C, et al. A reinforcement message based on bone turnover marker response influences long-term persistence with risedronate in osteoporosis: the IMPACT study. J Bone Miner Res 2003;18:S374
6. Hannon R, Blumsohn A, Naylor K, et al. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 1998;13:1124-33
7. Braga de Castro MA, Hannon R, Eastell R. Monitoring alendronate therapy for osteoporosis. J Bone Miner Res 1999;14:602-8
8. Efron B, Stein C. The jackknife estimate of variance. Ann Stat 1981;9:586-96
9. McClung M, San Martin J, Miller PD, et al. Teriparatide and alendronate increase bone mass by opposite effects on bone remodeling. Arch Intern Med 2005;165(15):1762-68
10. Ettinger B, San Martin J, Crans G, et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004;19:745-51
11. Blumsohn A, Brixen K, Sigurdsson G, et al. Early change in bone turnover following teriparatide (RhPTH 1-34) In the Eurofors Study: influence of prior therapy and association with BMD change at one year. J Bone Miner Res 2005;20(Suppl 1):S411
12. Clowes JA, Peel NF, Hannon RA, et al Relative utility of new serum markers of bone turnover for monitoring raloxifene therapy. J Bone Miner Res 2003;18(Suppl 2):SU373
13. Reginster JY, Sarkar S, Zegels B, et al. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 2004;34:344-51
14. Clowes JA, Hannon RA, Yap TS, et al. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 2002;30:886-90
15. Chen P, Miller PD, Delmas PD, et al. Change in bone mineral density (BMD) and fracture risk reduction in teriparatide-treated women with osteoporosis. J Bone Miner Res 2005;20(Suppl 1): S175
16. Cosman F, Nieves J, Zion M, et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005;353(6):566-75
17. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-15
18. Finkelstein JS, Klibanski A, Schaefer EH, et al. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 1994;331:1618-23
19. Ste-Marie LG, Schwartz SL, Hossain AM, et al. Effect of teriparatide [rh parathyroid hormone (1-34)] on bone density when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res 2005 (in press)
20. Deal C, Omizo M, Schwartz EN, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Min Res 2005;20:1905-11
21. Lomeo A, Bolner A. Stability of several biochemical markers of bone metabolism. Clin Chem 2000;46(8):1200-02